X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.

@article{Lamas2012XrayCG,
  title={X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.},
  author={Mar{\'i}a Jes{\'u}s Lamas and Goretti Duran and Antonio G{\'o}mez and Emilia Balboa and Urbano Anido and Beatriz Bern{\'a}rdez and Pablo Rana-Diez and Rafael Mart{\'i}n-Granizo L{\'o}pez and {\'A}ngel Carracedo and Francisco Barros},
  journal={International journal of radiation oncology, biology, physics},
  year={2012},
  volume={82 1},
  pages={138-44}
}
PURPOSE 5-Fluorouracil-based chemoradiotherapy before total mesorectal excision is currently the standard treatment of Stage II and III rectal cancer patients. We used known predictive pharmacogenetic biomarkers to identify the responders to preoperative chemoradiotherapy in our series. METHODS AND MATERIALS A total of 93 Stage II-III rectal cancer patients were genotyped using peripheral blood samples. The genes analyzed were X-ray cross-complementing group 1 (XRCC1), ERCC1, MTHFR, EGFR… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Similar Papers

Loading similar papers…